Physician profile
John C Weiss
NPI 1215021084
$1,847.46
in general payments reported to CMS, 2019-2025
29 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $134 · 2021: $428 · 2022: $123 · 2023: $13.00 · 2024: $181 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $259.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $222.88 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $134.51 | 2021-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $112.02 | 2021 | |
| Abbvie INC. | $95.43 | 2021-2025 | |
| Glaxosmithkline, LLC. | $70.42 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $66.96 | 2022-2025 | Camzyos, Eliquis |
| Phathom Pharmaceuticals, INC. | $58.32 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $51.93 | 2021-2025 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $39.50 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $38.04 | 2019-2021 | |
| Corcept Therapeutics | $37.76 | 2025 | Korlym |
| Pfizer INC. | $26.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.17 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.40 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.89 | 2021 | |
| Shield Therapeutics INC | $16.24 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.02 | 2022 | |
| Boston Scientific Corporation | $15.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.49 | 2021 | |
| Amgen INC. | $15.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.69 | 2025 | Strensiq |
| Ani Pharmaceuticals, INC. | $14.53 | 2024 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $13.00 | 2023 | Cologuard Collection Kit |
| Grifols USA, LLC | $12.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.00 | 2019 | |
| Biomerieux INC | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.